Microbial Fermentation CMO Market

Microbial Fermentation CMO Market (2nd Edition): Industry Trends and Global Forecasts, Till 2035: Type of Expression System (Bacterial Expression Systems, Yeast Expression Systems and Other Expression Systems), Type of Biologic (Recombinant Proteins, Enzymes, Plasmid DNA, Antibodies and Others), Company Size (Small, Mid-sized, Large and Very Large), End-User (Pharma / Biotech Companies and Academic/ Research Institutes) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    181

  • Pages
    327

  • View Count
    23984

Table Of Contents

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Future Estimates

3.2.2. Currency Coverage and Foreign Exchange Rates
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
3.2.2.4. Strategies for Mitigating Foreign Exchange Risk

3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers

3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY
4.1 Chapter Overview

5. INTRODUCTION
5.1 Chapter Overview
5.2. Types of Expression Systems
5.2.1. Microbial Expression Systems
5.2.1.1. Bacterial Expression Systems
5.2.1.2. Fungal Expression Systems
5.2.1.3. Yeast Expression Systems
5.2.1.4 Mammalian versus Microbial Expression Systems

5.3. Stages of the Microbial Manufacturing Process
5.3.1. Cell Banking
5.3.2. Upstream Bioprocessing
5.3.3. Fermentation
5.3.4. Downstream Bioprocessing

5.4. Overview of Contract Manufacturing
5.5. Need for Outsourcing Microbial Manufacturing
5.6. Commonly Outsourced Operations in Microbial Contract Manufacturing Industry
5.7. Advantages and Disadvantages Associated with Outsourcing Manufacturing Services
5.8. Key Considerations while Selecting a CMO Partner

6. MARKET LANDSCAPE: MICROBIAL FERMENTATION CONTRACT MANUFACTURERS
6.1. Chapter Overview
6.2. Microbial Fermentation Contract Manufacturers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Type of Microbial Fermentation Service Offered
6.2.5. Analysis by Type of Microbial Expression System Used
6.2.6. Analysis by GMP Compliance
6.2.7. Analysis by Scale of Operation
6.2.8. Analysis by Type of Biologic Manufactured
6.2.9. Analysis by Type of Fermenter
6.2.10. Analysis by Location of Microbial Fermentation Facilities

7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. Company Competitiveness Analysis: Microbial Fermentation Contract Manufacturers
7.4.1. Players based in North America (Peer Group I)
7.4.2. Players based in Europe (Peer Group II)
7.4.3. Players based in Asia-Pacific and Rest of the World (Peer Group III)

8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Detailed Profiles of Leading Players
8.2.1. AGC Biologics
8.2.1.1. Company Overview
8.2.1.2. Microbial Fermentation Service Portfolio
8.2.1.3. Microbial Fermentation Facilities
8.2.1.4. Recent Developments and Future Outlook

8.2.2. Aldevron
8.2.2.1. Company Overview
8.2.2.2. Microbial Fermentation Service Portfolio
8.2.2.3. Microbial Fermentation Facilities
8.2.2.4. Recent Developments and Future Outlook

8.2.3. BioVectra
8.2.3.1. Company Overview
8.2.3.2. Microbial Fermentation Service Portfolio
8.2.3.3. Microbial Fermentation Facilities
8.2.3.4. Recent Developments and Future Outlook

8.2.4. EirGenix
8.2.4.1. Company Overview
8.2.4.2. Financial Information
8.2.4.3. Microbial Fermentation Service Portfolio
8.2.4.4. Microbial Fermentation Facilities
8.2.4.5. Recent Developments and Future Outlook

8.2.5. EtinPro
8.2.5.1. Company Overview
8.2.5.2. Microbial Fermentation Service Portfolio
8.2.5.3. Microbial Fermentation Facilities
8.2.5.4. Recent Developments and Future Outlook

8.2.6. Eurogentec
8.2.6.1. Company Overview
8.2.6.2. Microbial Fermentation Service Portfolio
8.2.6.3. Microbial Fermentation Facilities
8.2.6.4. Recent Developments and Future Outlook

8.2.7. Northway Biotech
8.2.7.1. Company Overview
8.2.7.2. Microbial Fermentation Service Portfolio
8.2.7.3. Microbial Fermentation Facilities
8.2.7.4. Recent Developments and Future Outlook

8.2.8. Stelis Biosource
8.2.8.1. Company Overview
8.2.8.2. Microbial Fermentation Service Portfolio
8.2.8.3. Microbial Fermentation Facilities
8.2.8.4. Recent Developments and Future Outlook

8.3. Short Profiles of Other Prominent Players
8.3.1. 53Biologics
8.3.1.1. Company Overview
8.3.1.2. Microbial Fermentation Service Portfolio
8.3.1.3. Microbial Fermentation Facilities

8.3.2. AbbVie Contract Manufacturing
8.3.2.1. Company Overview
8.3.2.2. Microbial Fermentation Service Portfolio
8.3.2.3. Microbial Fermentation Facilities

8.3.3. Ajinomoto Bio-Pharma Services
8.3.3.1. Company Overview
8.3.3.2. Microbial Fermentation Service Portfolio
8.3.3.3. Microbial Fermentation Facilities

8.3.4. Aumgene Biosciences
8.3.4.1. Company Overview
8.3.4.2. Microbial Fermentation Service Portfolio
8.3.4.3. Microbial Fermentation Facilities

8.3.5. BioCina
8.3.5.1. Company Overview
8.3.5.2. Microbial Fermentation Service Portfolio
8.3.5.3. Microbial Fermentation Facilities

8.3.6. Creative Biogene
8.3.6.1. Company Overview
8.3.6.2. Microbial Fermentation Service Portfolio
8.3.6.3. Microbial Fermentation Facilities

8.3.7. Eubiologics
8.3.7.1. Company Overview
8.3.7.2. Microbial Fermentation Service Portfolio
8.3.7.3. Microbial Fermentation Facilities

8.3.8. Eurofins
8.3.8.1. Company Overview
8.3.8.2. Microbial Fermentation Service Portfolio
8.3.8.3. Microbial Fermentation Facilities

8.3.9. FUJIFILM Diosynth Biotechnologies
8.3.9.1. Company Overview
8.3.9.2. Microbial Fermentation Service Portfolio
8.3.9.3. Microbial Fermentation Facilities

8.3.10. KBI Biopharma
8.3.10.1. Company Overview
8.3.10.2. Microbial Fermentation Service Portfolio
8.3.10.3. Microbial Fermentation Facilities

8.3.11. Lonza
8.3.11.1. Company Overview
8.3.11.2. Microbial Fermentation Service Portfolio
8.3.11.3. Microbial Fermentation Facilities

8.3.12. Menarini Biotech
8.3.12.1. Company Overview
8.3.12.2. Microbial Fermentation Service Portfolio
8.3.12.3. Microbial Fermentation Facilities

8.3.13. Mycenax Biotech
8.3.13.1. Company Overview
8.3.13.2. Microbial Fermentation Service Portfolio
8.3.13.3. Microbial Fermentation Facilities

8.3.14. WACKER
8.3.14.1. Company Overview
8.3.14.2. Microbial Fermentation Service Portfolio
8.3.14.3. Microbial Fermentation Facilities

8.3.15. WuXi Biologics
8.3.15.1. Company Overview
8.3.15.2. Microbial Fermentation Service Portfolio
8.3.15.3. Microbial Fermentation Facilities

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Microbial Fermentation CMO: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnerships
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Biologic Manufactured
9.3.5. Analysis by Type of Partner
9.3.6. Most Active Players: Distribution by Number of Partnerships
9.3.7. Analysis by Geography
9.3.7.1. Intracontinental and Intercontinental Agreements
9.3.7.2. International and Local Deals

10. RECENT EXPANSIONS
10.1. Chapter Overview
10.2. Microbial Fermentation CMO: Recent Expansions
10.2.1. Analysis by Year of Expansion 
10.2.2. Analysis by Type of Expansion
10.2.3. Analysis by Year and Type of Expansion
10.2.4. Analysis by Microbial Fermentation Capacity
10.2.5. Analysis by Type of Biologic Manufactured
10.2.6. Analysis by Location of Expanded Facility
10.2.7. Analysis by Type of Expansion Location of Expanded Facility
10.2.8. Most Active Players: Distribution by Number of Recent Expansions

10.2.9. Analysis by Geography
10.2.9.1 Analysis by Continent
10.2.9.2 Analysis by Country

11. BIG PHARMA INITITATIVES IN MICROBIAL MANUFACTURING
11.1. Chapter Overview
11.2. List of Microbial Biopharmaceutical Manufacturing Initiatives of Big Pharma Players
11.2.1. Analysis by Number of Initiatives
11.2.2. Analysis by Year of Initiative Undertaken
11.2.3. Analysis by Company and Year of Initiative Undertaken
11.2.4. Analysis by Purpose of Initiative Undertaken
11.2.5. Analysis by Company and Purpose of Initiative Undertaken
11.2.6. Analysis by Type of Initiative
11.2.7. Analysis by Scale of Operation
11.2.8. Analysis by Type of Drug Molecule
11.2.9. Analysis by Type of Microbial Expression System Used
11.2.10. Geographical Analysis by Amount Invested

11.3. Competitive Benchmarking of Big Pharmaceutical Players
11.3.1. Concluding Remarks

12. ATTRACTIVENESS COMPETITION MATRIX
12.1. Chapter Overview
12.2. AC Matrix: An Overview
12.2.1. Strong Business Segment
12.2.2. Average Business Segment
12.2.3. Weak Business Segment

12.3. AC Matrix: Analytical Methodology
12.4. AC Matrix: Contract Manufacturing Scenario in North America
12.5. AC Matrix: Contract Manufacturing Scenario in Europe
12.6. AC Matrix: Contract Manufacturing Scenario in Asia Pacific and Middle East

13. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
13.1. Chapter Overview
13.2. Assumptions and Parameter Definitions
13.2.1. Scenario 1
13.2.2. Scenario 2
13.2.3. Scenario 3
13.2.4. Scenario 4

13.3. Concluding Remarks

14. CASE STUDY I: MICROBIAL FERMENTATION TECHNOLOGY PLATFORMS
14.1. Chapter Overview
14.2. Technology Platforms Commonly Used for Microbial Fermentation
14.3. Upcoming Platforms-General Technologies

15. CASE STUDY II: COMPARISON OF SMALL MOLECULE AND LARGE MOLECULE DRUGS / THERAPIES
15.1. Chapter Overview
15.2. Small Molecule and Large Molecule Drugs / Therapies
15.2.1. Comparison of Key Characteristics

15.2.2. Comparison of Microbial Manufacturing Process
15.2.2.1. Microbial Contract Manufacturers Providing Services for Small Molecules

15.2.3. Comparison of Key Manufacturing-related Challenges

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
16.1. Chapter Overview
16.2. Market Drivers
16.3. Market Restraints
16.4. Market Opportunities
16.5. Market Challenges
16.6. Conclusion

17. GLOBAL MICROBIAL FERMENTATION CMO MARKET
17.1. Chapter Overview
17.2. Key Assumptions and Methodology

17.3. Global Microbial Fermentation CMO Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.1. Scenario Analysis
17.3.1.1. Conservative Scenario
17.3.1.2. Optimistic Scenario

17.4. Key Market Segmentations

18. MICROBIAL FERMENTATION CMO MARKET, BY TYPE OF EXPRESSION SYSTEM USED
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Microbial Fermentation CMO Market: Distribution by Type of Expression System Used, 2018, 2024 and 2035
18.3.1. Bacterial Expression Systems Market: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.2. Yeast Expression Systems Market: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.3. Other Expression Systems Market: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

18.4. Data Triangulation and Validation

19. MICROBIAL FERMENTATION CMO MARKET, BY TYPE OF BIOLOGIC
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Microbial Fermentation CMO Market: Distribution by Type of Biologic, 2018, 2024 and 2035
19.3.1. Recombinant Proteins Market: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
19.3.2. Enzymes Market: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
19.3.3. Plasmid DNA Market: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
19.3.4. Antibodies Market: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
19.3.5. Other Biologics Market: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

19.4. Data Triangulation and Validation

20. MICROBIAL FERMENTATION CMO MARKET, BY COMPANY SIZE
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Microbial Fermentation CMO Market: Distribution by Company Size, 2018, 2024 and 2035
20.3.1. Small Companies: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.2. Mid-Sized Companies: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.3. Large and Very Large Companies:: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

20.4. Data Triangulation and Validation

21. MICROBIAL FERMENTATION CMO MARKET, BY END-USERS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Microbial Fermentation CMO Market: Distribution by End-User, 2018, 2024 and 2035
21.3.1. Pharma / Biotech Companies Market: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
21.3.2. Academic / Research Institutes Market: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

21.4. Data Triangulation and Validation

22. MICROBIAL FERMENTATION CMO MARKET, BY KEY GEOGRAPHICAL REGIONS
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Microbial Fermentation CMO Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
22.3.1. North America Market: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.1.1 Bacterial Expression Systems Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.1.2 Yeast Expression Systems Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.1.3 Other Expression Systems Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.1.4 Recombinant Proteins Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.1.5 Enzymes Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.1.6 Plasmid DNA Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.1.7 Antibodies Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.1.8 Other Biologics Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.1.9 Small Companies Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.1.10 Mid-Sized Companies Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.1.11 Large and Very Large Companies Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.1.12 Pharma / Biotech Companies Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.1.13 Academic / Research Institutes Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

22.3.2. Europe Market: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2.1 Bacterial Expression Systems Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2.2 Yeast Expression Systems Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2.3 Other Expression Systems Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2.4 Recombinant Proteins Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2.5 Enzymes Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2.6 Plasmid DNA Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2.7 Antibodies Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2.8 Other Biologics Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2.9 Small Companies Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2.10 Mid-Sized Companies Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2.11 Large and Very Large Companies Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2.12 Pharma/ Biotech Companies Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2.13 Academic/ Research Institutes Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

22.3.3. Asia-Pacific Market: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.3.1 Bacterial Expression Systems Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.3.2 Yeast Expression Systems Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.3.3 Other Expression Systems Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.3.4 Recombinant Proteins Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.3.5 Enzymes Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.3.6 Plasmid DNA Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.3.7 Antibodies Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.3.8 Other Biologics Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.3.9 Small Companies Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.3.10 Mid-Sized Companies Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.3.11 Large and Very Large Companies Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.3.12 Pharma/ Biotech Companies Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.3.13 Academic/ Research Institutes Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

22.3.4. Rest of the World Market: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.4.1 Bacterial Expression Systems Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.4.2 Yeast Expression Systems Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.4.3 Other Expression Systems Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.4.4 Recombinant Proteins Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.4.5 Enzymes Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.4.6 Plasmid DNA Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.4.7 Antibodies Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.4.8 Other Biologics Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.4.9 Small Companies Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.4.10 Mid-Sized Companies Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.4.11 Large and Very Large Companies Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.4.12 Pharma/ Biotech Companies Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.4.13 Academic/ Research Institutes Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

22.4. Data Triangulation and Validation

23. CONCLUDING REMARKS
23.1. Chapter Overview

24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Meteoric Biopharmaceuticals
24.2.1. Company Snapshot
24.2.2. Interview Transcript

24.3. List Biological Laboratories
24.3.1. Company Snapshot
24.3.2. Interview Transcript

24.4. OLON
24.4.1. Company Snapshot
24.4.2. Interview Transcript

24.5. Luina Bio
24.5.1. Company Snapshot
24.5.2. Interview Transcript

24.6. WACKER Biotech
24.6.1. Company Snapshot
24.6.2. Interview Transcript

25. APPENDIX 1: TABULATED DATA

26. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 5.1 Types of Expression Systems
Figure 5.2 Stages of Microbial Manufacturing Process
Figure 5.3 Overview of Cell Bank Systems
Figure 5.4 Types of Third-Party Service Providers
Figure 5.5 Commonly Outsourced Microbial Contract Biomanufacturing Operations
Figure 5.6 Advantages and Disadvantages Associated with Outsourcing Manufacturing Services
Figure 6.1 Microbial Fermentation Contract Manufacturers: Distribution by Year of Establishment
Figure 6.2 Microbial Fermentation Contract Manufacturers: Distribution by Company Size
Figure 6.3 Microbial Fermentation Contract Manufacturers: Distribution by Location of Headquarters
Figure 6.4 Microbial Fermentation Contract Manufacturers: Distribution by Type of Microbial Fermentation Service Offered
Figure 6.5 Microbial Fermentation Contract Manufacturers: Distribution by Type of Microbial Expression System Used
Figure 6.6 Microbial Fermentation Contract Manufacturers: Distribution by GMP Compliance
Figure 6.7 Microbial Fermentation Contract Manufacturers: Distribution by Scale of Operation
Figure 6.8 Microbial Fermentation Contract Manufacturers: Distribution by Type of Biologic Manufactured
Figure 6.9 Microbial Fermentation Contract Manufacturers: Distribution by Type of Fermenter
Figure 6.10 Microbial Fermentation Contract Manufacturers: Distribution by Location of Microbial Fermentation Facilities
Figure 7.1 Company Competitiveness Analysis: Players based in North America (Peer Group I)
Figure 7.2 Company Competitiveness Analysis: Players based in Europe (Peer Group II)
Figure 7.3 Company Competitiveness Analysis: Players based in Asia-Pacific and Rest of the World (Peer Group III)
Figure 8.1 EirGenix: Annual Revenues, FY 2019-FY 2023 (TWD Million)
Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2020-2024
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.6 Most Active Players: Distribution by Number of Partnerships
Figure 9.7 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 9.8 Partnerships and Collaborations: International and Local Deals
Figure 10.1 Recent Expansions: Cumulative Year-wise Trend, 2020-2024
Figure 10.2 Recent Expansions: Distribution by Type of Expansion
Figure 10.3 Recent Expansions: Distribution by Year and Type of Expansion
Figure 10.4 Recent Expansions: Distribution by Microbial Fermentation Capacity
Figure 10.5 Recent Expansions: Distribution by Type of Biologic Manufactured
Figure 10.6 Recent Expansions: Distribution by Location of Expanded Facility
Figure 10.7 Recent Expansions: Distribution by Type of Expansion and Location of Expanded Facility
Figure 10.8 Most Active Players: Distribution by Number of Recent Expansions
Figure 10.9 Recent Expansions: Distribution by Continent
Figure 10.10 Recent Expansions: Distribution by Location of Expanded Facility (Country)
Figure 11.1 Big Pharma Players: Distribution by Number of Microbial Biopharmaceutical Manufacturing Focused Initiatives
Figure 11.2 Big Pharma Players: Cumulative Distribution by Year of Initiative
Figure 11.3 Big Pharma Players: Distribution by Company and Year of Initiative
Figure 11.4 Big Pharma Players: Distribution by Purpose of Initiative
Figure 11.5 Big Pharma Players: Distribution by Company and Purpose of Initiative
Figure 11.6 Big Pharma Players: Distribution by Type of Initiative
Figure 11.7 Big Pharma Players: Distribution by Scale of Operation
Figure 11.8 Big Pharma Players: Distribution by Type of Drug Molecule
Figure 11.9 Big Pharma Players: Distribution by Type of Biologic Manufactured
Figure 11.10 Big Pharma Players: Distribution by Type of Microbial Expression System Used
Figure 11.11 Big Pharma Players: Distribution by Location of Initiative
Figure 11.12 Big Pharma Players: Distribution by Company and Location of Initiative
Figure 11.13 Harvey Ball Analysis: Big Pharma Investment Summary
Figure 12.1 Attractiveness Competition Matrix: Pictorial Representation
Figure 12.2 Attractiveness Competition Matrix: Positioning of Different Biologics in North America
Figure 12.3 Attractiveness Competition Matrix: Positioning of Different Biologics in Europe
Figure 12.4 Attractiveness Competition Matrix: Positioning of Different Biologics in Asia Pacific and Middle East
Figure 13.1 Make versus Buy Decision Making Framework
Figure 13.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 14.1 Fermentation Technology / Platform: Distribution by Type of Microbial Expression System Used
Figure 14.2 Fermentation Technology / Platform: Distribution by Purpose
Figure 15.1 Small Molecules versus Large Molecules: Comparison of Key Characteristics
Figure 15.2 Small Molecules versus Large Molecule: Comparison of Manufacturing Process
Figure 15.3 Microbial Contract Manufacturing: Distribution by Type of Product
Figure 15.4 Microbial Contract Manufacturing: Distribution by Type of Microbial Expression System Used
Figure 17.1 Global Microbial Fermentation CMO Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.2 Global Microbial Fermentation CMO Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Billion)
Figure 17.3 Global Microbial Fermentation CMO Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Billion)
Figure 18.1 Microbial Fermentation CMO Market: Distribution by Type of Expression System, 2018, 2024 and 2035
Figure 18.2 Bacterial Expression Systems Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.3 Yeast Expression Systems Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.4 Other Expression Systems Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.1 Microbial Fermentation CMO Market: Distribution by Type of Biologic, 2019, 2024 and 2035
Figure 19.2 Recombinant Proteins Market, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.3 Enzymes Market, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.4 Plasmid DNA Market, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.5 Antibodies Market, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.6 Other Biologics Market, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.1 Microbial Fermentation CMO Market: Distribution by Company Size, 2018, 2024 and 2035
Figure 20.2 Small Companies Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.3 Mid-Sized Companies Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.4 Large and Very Large Companies Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 21.1 Microbial Fermentation CMO Market: Distribution by End-User, 2118, 2124 and 2135
Figure 21.2 Pharma/ Biotech Companies Market, Historical Trends (2118-2123) and Forecasted Estimates (2124-2135) (USD Billion)
Figure 21.3 Academic/ Research Institutes Market, Historical Trends (2118-2123) and Forecasted Estimates (2124-2135) (USD Billion)
Figure 22.1 Microbial Fermentation CMO Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
Figure 22.2 North America Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.3 Bacterial Expression Systems Market in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.4 Yeast Expression Systems Market in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)(USD Billion)
Figure 22.5 Other Expression Systems Market in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.6 Recombinant Proteins Market in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.7 Enzymes Market in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.8 Plasmid DNA Market in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.9 Antibodies Market in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.10 Other Biologics Market in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.11 Small Companies Market in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.12 Mid-Sized Companies Market in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.13 Large and Very Large Companies Market in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.14 Pharma/ Biotech Companies Market in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.15 Academic / Research Institutes Market in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.16 Europe Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.17 Bacterial Expression Systems Market in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.18 Yeast Expression Systems Market in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.19 Other Expression Systems Market in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.20 Recombinant Proteins Market in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.22 Enzymes Market in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.22 Plasmid DNA Market in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.23 Antibodies Market in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.24 Other Biologics Market in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.25 Small Companies Market in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.26 Mid-Sized Companies Market in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.27 Large and Very Large Companies Market in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.28 Pharma / Biotech Companies Market in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.29 Academic / Research Institutes Market in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.30 Asia-Pacific Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.31 Bacterial Expression Systems Market in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.32 Yeast Expression Systems Market in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.33 Other Expression Systems Market in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.34 Recombinant Proteins Market in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.35 Enzymes Market in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.36 Plasmid DNA Market in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.37 Antibodies Market in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.38 Other Biologics Market in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.39 Small Companies Market in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.40 Mid-Sized Companies Market in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.41 Large and Very Large Companies Market in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.42 Pharma / Biotech Companies Market in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.43 Academic / Research Institutes Market in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.44 Rest of the World Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.45 Bacterial Expression System Market in Rest of the World, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.46 Yeast Expression System Market in Rest of the World, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.47 Other Expression System Market in Rest of the World, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.48 Recombinant Proteins Market in Rest of the World, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.49 Enzymes Market in Rest of the World, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.50 Plasmid DNA Market in Rest of the World, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.51 Antibodies Market in Rest of the World, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.52 Other Biologics Market in Rest of the World, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.53 Small Companies Market in Rest of the World, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.54 Mid-Sized Companies Market in Rest of the World, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.55 Large and Very Large Companies Market in Rest of the World, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.56 Pharma/ Biotech Companies Market in Rest of the World, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.57 Academic/ Research Institutes Market in Rest of the World, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 23.1 Concluding Remarks: Market Landscape of Microbial Fermentation Contract Manufacturers
Figure 23.2 Concluding Remarks: Partnerships and Collaborations
Figure 23.3 Concluding Remarks: Recent Expansions
Figure 23.4 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 5.1 Mammalian versus Microbial Expression Systems
Table 6.1 List of Microbial Fermentation Contract Manufacturers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 6.2 List of Microbial Fermentation Contract Manufacturers: Information on Microbial Fermentation Service Offered and Microbial Expression System Used
Table 6.3 List of Microbial Fermentation Contract Manufacturers: Information on GMP Compliance, Scale of Operation, Type of Biologic Manufactured and Type of Fermenter
Table 6.4 List of Microbial Contract Manufacturers: Information on Location of Microbial Fermentation Facilities
Table 8.1 Microbial Fermentation Contract Manufacturers: List of Companies Profiled
Table 8.2 AGC Biologics: Company Overview
Table 8.3 AGC Biologics: Microbial Fermentation Service Portfolio
Table 8.4 AGC Biologics: Microbial Fermentation Facilities
Table 8.5 AGC Biologics: Recent Developments and Future Outlook
Table 8.6 Aldevron: Company Overview
Table 8.7 Aldevron: Microbial Fermentation Service Portfolio
Table 8.8 Aldevron: Microbial Fermentation Facilities
Table 8.9 Aldevron: Recent Developments and Future Outlook
Table 8.10 BioVectra: Company Overview
Table 8.11 BioVectra: Microbial Fermentation Service Portfolio
Table 8.12 BioVectra: Microbial Fermentation Facilities
Table 8.13 BioVectra: Recent Developments and Future Outlook
Table 8.14 EirGenix: Company Overview
Table 8.15 EirGenix: Microbial Fermentation Service Portfolio
Table 8.16 EirGenix: Microbial Fermentation Facilities
Table 8.17 Etinpro: Company Overview
Table 8.18 Etinpro: Microbial Fermentation Service Portfolio
Table 8.19 Etinpro: Microbial Fermentation Facilities
Table 8.20 Eurogentec: Company Overview
Table 8.21 Eurogentec: Microbial Fermentation Service Portfolio
Table 8.22 Eurogentec: Microbial Fermentation Facilities
Table 8.23 Northway Biotech: Company Overview
Table 8.24 Northway Biotech: Microbial Fermentation Service Portfolio
Table 8.25 Northway Biotech: Microbial Fermentation Facilities
Table 8.26 Northway Biotech: Recent Developments and Future Outlook
Table 8.27 Stelis Biopharma: Company Overview
Table 8.28 Stelis Biopharma: Microbial Fermentation Service Portfolio
Table 8.29 Stelis Biopharma: Microbial Fermentation Facilities
Table 8.30 53Biologics: Company Overview
Table 8.31 53Biologics: Microbial Fermentation Service Portfolio
Table 8.32 53Biologics: Microbial Fermentation Facilities
Table 8.33 Abbvie Contract Manufacturing: Company Overview
Table 8.34 Abbvie Contract Manufacturing: Microbial Fermentation Service Portfolio
Table 8.35 Abbvie Contract Manufacturing: Microbial Fermentation Facilities
Table 8.36 Ajinomoto Bio-Pharma Services: Company Overview
Table 8.37 Ajinomoto Bio-Pharma Services: Microbial Fermentation Service Portfolio
Table 8.38 Ajinomoto Bio-Pharma Services: Microbial Fermentation Facilities
Table 8.39 Aumgene Biosciences: Company Overview
Table 8.40 Aumgene Biosciences: Microbial Fermentation Service Portfolio
Table 8.41 Aumgene Biosciences: Microbial Fermentation Facilities
Table 8.42 BioCina: Company Overview
Table 8.43 BioCina: Microbial Fermentation Service Portfolio
Table 8.44 BioCina: Microbial Fermentation Facilities
Table 8.45 Creative Biogene: Company Overview
Table 8.46 Creative Biogene: Microbial Fermentation Service Portfolio
Table 8.47 Creative Biogene: Microbial Fermentation Facilities
Table 8.48 Eubiologics: Company Overview
Table 8.49 Eubiologics: Microbial Fermentation Service Portfolio
Table 8.50 Eubiologics: Microbial Fermentation Facilities
Table 8.51 Eurofins: Company Overview
Table 8.52 Eurofins: Microbial Fermentation Service Portfolio
Table 8.53 Eurofins: Microbial Fermentation Facilities
Table 8.54 FUJIFILM Diosynth Biotechnologies: Company Overview
Table 8.55 FUJIFILM Diosynth Biotechnologies: Microbial Fermentation Service Portfolio
Table 8.56 FUJIFILM Diosynth Biotechnologies: Microbial Fermentation Facilities
Table 8.57 KBI Biopharma: Company Overview
Table 8.58 KBI Biopharma: Microbial Fermentation Service Portfolio
Table 8.59 KBI Biopharma: Microbial Fermentation Facilities
Table 8.60 Lonza: Company Overview
Table 8.61 Lonza: Microbial Fermentation Service Portfolio
Table 8.62 Lonza: Microbial Fermentation Facilities
Table 8.63 Menarini Biotech: Company Overview
Table 8.64 Menarini Biotech: Microbial Fermentation Service Portfolio
Table 8.65 Menarini Biotech: Microbial Fermentation Facilities
Table 8.66 Mycenax Biotech: Company Overview
Table 8.67 Mycenax Biotech: Microbial Fermentation Service Portfolio
Table 8.68 Mycenax Biotech: Microbial Fermentation Facilities
Table 8.69 WACKER: Company Overview
Table 8.70 WACKER: Microbial Fermentation Service Portfolio
Table 8.71 WACKER: Microbial Fermentation Facilities
Table 8.72 WuXi Biologics: Company Overview
Table 8.73 WuXi Biologics: Microbial Fermentation Service Portfolio
Table 8.74 WuXi Biologics: Microbial Fermentation Facilities
Table 9.1 Microbial Fermentation CMO: List of Partnerships and Collaborations, 2020-2024
Table 10.1 Microbial Fermentation CMO: List of Recent Expansions, 2020-2024
Table 11.1 Big Pharmaceutical Players: List of Initiatives
Table 14.1 List of Technology / Platforms for Microbial Manufacturing
Table 15.1 List of Microbial Contract Biomanufacturers
Table 15.2 Small Molecules and Large Molecules: Comparison of Development Characteristics
Table 25.1 Microbial Fermentation Contract Manufacturers: Distribution by Year of Establishment
Table 25.2 Microbial Fermentation Contract Manufacturers: Distribution by Company Size
Table 25.3 Microbial Fermentation Contract Manufacturers: Distribution by Location of Headquarters
Table 25.4 Microbial Fermentation Contract Manufacturers: Distribution by Type of Microbial Fermentation Service Offered
Table 25.5 Microbial Fermentation Contract Manufacturers: Distribution by Type of Microbial Expression System Used
Table 25.6 Microbial Fermentation Contract Manufacturers: Distribution by GMP Compliance
Table 25.7 Microbial Fermentation Contract Manufacturers: Distribution by Scale of Operation
Table 25.8 Microbial Fermentation Contract Manufacturers: Distribution by Type of Biologic Manufactured
Table 25.9 Microbial Fermentation Contract Manufacturers: Distribution by Type of Fermenter
Table 25.10 Microbial Fermentation Contract Manufacturers: Distribution by Location of Microbial Fermentation Facilities
Table 25.11 Partnerships and Collaborations: Cumulative Year-wise Trend, 2020-2024
Table 25.12 Partnerships and Collaborations: Distribution by Type of Partnership
Table 25.13 Partnerships and Collaborations: Distribution by Type of Biologic
Table 25.14 Partnerships and Collaborations: Distribution by Type of Partner
Table 25.15 Most Active Players: Distribution by Number of Partnerships
Table 25.16 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
Table 25.17 Partnerships and Collaborations: Local and International Agreements
Table 25.18 Recent Expansions: Cumulative Year-wise Trend, 2020-2024
Table 25.19 Recent Expansions: Distribution by Type of Expansion
Table 25.20 Recent Expansions: Distribution by Year and Type of Expansion
Table 25.21 Recent Expansions: Distribution by Microbial Fermentation Capacity
Table 25.22 Recent Expansions: Distribution by Type of Biologic
Table 25.23 Recent Expansions: Distribution by Location of Expanded Facility
Table 25.24 Recent Expansions: Distribution by Type of Expansion and Location of Expanded Facility
Table 25.25 Most Active Players: Distribution by Number of Recent Expansions
Table 25.26 Recent Expansions: Distribution by Continent
Table 25.27 Recent Expansions: Distribution by Location of Expanded Facility (Country)
Table 25.28 Big Pharma Players: Distribution by Number of Microbial Biopharmaceutical Manufacturing Focused Initiatives
Table 25.29 Big Pharma Players: Cumulative Distribution by Year of Initiative
Table 25.30 Big Pharma Players: Distribution by Company and Year of Initiative
Table 25.31 Big Pharma Players: Distribution by Purpose of Initiative
Table 25.32 Big Pharma Players: Distribution by Company and Purpose of Initiative
Table 25.33 Big Pharma Players: Distribution by Type of Initiative
Table 25.34 Big Pharma Players: Distribution by Development Scale
Table 25.35 Big Pharma Players: Distribution by Type of Drug Molecule
Table 25.36 Big Pharma Players: Distribution by Type of Biologic Manufactured
Table 25.37 Big Pharma Players: Distribution by Type of Microbial Expression System Used
Table 25.40 Big Pharma Players: Distribution by Location of Initiative
Table 25.41 Big Pharma Players: Distribution by Company and Location of Initiative
Table 25.28 Fermentation Technology / Platform: Distribution by Type of Microbial Expression System Used
Table 25.29 Fermentation Technology / Platform: Distribution by Purpose
Table 25.42 Microbial Contract Manufacturing: Distribution by Type of Product
Table 25.43 Microbial Contract Manufacturing: Distribution by Type of Microbial Expression System Used
Table 25.44 Global Microbial Fermentation CMO Market: Historical Trends, 2018-2023 (USD Billion)
Table 25.45 Global Microbial Fermentation CMO Market: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.46 Microbial Fermentation CMO Market: Distribution by Type of Expression System, 2018, 2024 and 2035
Table 25.47 Bacterial Expression Systems Market: Historical Trends, 2018-2023 (USD Billion)
Table 25.48 Bacterial Expression Systems Market: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.49 Yeast Expression Systems Market: Historical Trends, 2018-2023 (USD Billion)
Table 25.50 Yeast Expression Systems Market: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.51 Other Expression Systems Market: Historical Trends, 2018-2023 (USD Billion)
Table 25.52 Other Expression Systems Market: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.53 Microbial Fermentation CMO Market: Distribution by Type of Biologic, 2018, 2024 and 2035
Table 25.54 Recombinant Proteins Market: Historical Trends, 2018-2023 (USD Billion)
Table 25.55 Recombinant Proteins Market: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.56 Enzymes Market: Historical Trends, 2018-2023 (USD Billion)
Table 25.57 Enzymes Market: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.58 Plasmid DNA Market: Historical Trends, 2018-2023 (USD Billion)
Table 25.59 Plasmid DNA Market: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.60 Antibodies Market: Historical Trends, 2018-2023 (USD Billion)
Table 25.61 Antibodies Market: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.62 Others Market: Historical Trends, 2018-2023 (USD Billion)
Table 25.63 Others Market: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.64 Microbial Fermentation CMO Market: Distribution by Company Size, 2018, 2024 and 2035
Table 25.65 Small Companies Market: Historical Trends, 2018-2023 (USD Billion)
Table 25.66 Small Companies Market: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.67 Mid-Sized Companies Market: Historical Trends, 2018-2023 (USD Billion)
Table 25.68 Mid-Sized Companies Market: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.69 Large and Very Large Companies Market: Historical Trends, 2018-2023 (USD Billion)
Table 25.70 Large and Very Large Companies Market: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.71 Microbial Fermentation CMO Market: Distribution by End-User, 2018, 2024 and 2035
Table 25.72 Pharma/ Biotech Companies Market: Historical Trends, 2018-2023 (USD Billion)
Table 25.73 Pharma/ Biotech Companies Market: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.74 Academic / Research Institutes Market: Historical Trends, 2018-2023 (USD Billion)
Table 25.75 Academic / Research Institutes Market: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.76 Microbial Fermentation CMO Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
Table 25.77 North America Market: Historical Trends, 2018-2023 (USD Billion)
Table 25.78 North America Market: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.79 Bacterial Expression System Market in North America: Historical Trends, 2018-2023 (USD Billion)
Table 25.80 Bacterial Expression Systems Market in North America: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.81 Yeast Expression Systems Market in North America: Historical Trends, 2018-2023 (USD Billion)
Table 25.82 Yeast Expression Systems Market in North America: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.83 Other Expression Systems Market in North America: Historical Trends, 2018-2023 (USD Billion)
Table 25.84 Other Expression Systems Market in North America: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.85 Recombinant Proteins Market in North America: Historical Trends, 2018-2023 (USD Billion)
Table 25.86 Recombinant Proteins Market in North America: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.87 Enzymes Market in North America: Historical Trends, 2018-2023 (USD Billion)
Table 25.88 Enzymes Market in North America: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.89 Plasmid DNA Market in North America: Historical Trends, 2018-2023 (USD Billion)
Table 25.90 Plasmid DNA Market in North America: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.91 Antibodies Market in North America: Historical Trends, 2018-2023 (USD Billion)
Table 25.92 Antibodies Market in North America: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.93 Other Biologics Market in North America: Historical Trends, 2018-2023 (USD Billion)
Table 25.94 Other Biologics Market in North America: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.95 Small Companies Market in North America: Historical Trends, 2018-2023 (USD Billion)
Table 25.96 Small Companies Market in North America: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.97 Mid-Sized Companies Market in North America: Historical Trends, 2018-2023 (USD Billion)
Table 25.98 Mid-Sized Companies Market in North America: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.99 Large and Very Large Companies Market in North America: Historical Trends, 2018-2023 (USD Billion)
Table 25.100 Large and Very Large Companies Market in North America: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.101 Pharma / Biotech Companies Market in North America: Historical Trends, 2018-2023 (USD Billion)
Table 25.102 Pharma / Biotech Companies Market in North America: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.103 Academic/ Research Institutes Market in North America: Historical Trends, 2018-2023 (USD Billion)
Table 25.104 Academic/ Research Institutes Market in North America: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.105 Europe Market: Historical Trends, 2018-2023 (USD Billion)
Table 25.106 Europe Market: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.107 Bacterial Expression System Market in Europe: Historical Trends, 2018-2023 (USD Billion)
Table 25.108 Bacterial Expression Systems Market in Europe: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.109 Yeast Expression Systems Market in Europe: Historical Trends, 2018-2023 (USD Billion)
Table 25.110 Yeast Expression Systems Market in Europe: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.111 Other Expression Systems Market in Europe: Historical Trends, 2018-2023 (USD Billion)
Table 25.112 Other Expression Systems Market in Europe: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.113 Recombinant Proteins Market in Europe: Historical Trends, 2018-2023 (USD Billion)
Table 25.114 Recombinant Proteins Market in Europe: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.115 Enzymes Market in Europe: Historical Trends, 2018-2023 (USD Billion)
Table 25.116 Enzymes Market in Europe: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.117 Plasmid DNA Market in Europe: Historical Trends, 2018-2023 (USD Billion)
Table 25.118 Plasmid DNA Market in Europe: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.119 Antibodies Market in Europe: Historical Trends, 2018-2023 (USD Billion)
Table 25.120 Antibodies Market in Europe: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.121 Other Biologics Market in Europe: Historical Trends, 2018-2023 (USD Billion)
Table 25.122 Other Biologics Market in Europe: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.123 Small Companies Market in Europe: Historical Trends, 2018-2023 (USD Billion)
Table 25.124 Small Companies Market in Europe: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.125 Mid-Sized Companies Market in Europe: Historical Trends, 2018-2023 (USD Billion)
Table 25.126 Mid-Sized Companies Market in Europe: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.127 Large and Very Large Companies Market in Europe: Historical Trends, 2018-2023 (USD Billion)
Table 25.128 Large and Very Large Companies Market in Europe: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.129 Pharma / Biotech Companies Market in Europe: Historical Trends, 2018-2023 (USD Billion)
Table 25.130 Pharma / Biotech Companies Market in Europe: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.131 Academic/ Research Institutes Market in Europe: Historical Trends, 2018-2023 (USD Billion)
Table 25.132 Academic/ Research Institutes Market in Europe: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.133 Asia-Pacific Market: Historical Trends, 2018-2023 (USD Billion)
Table 25.134 Asia-Pacific Market: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.135 Bacterial Expression System Market in Asia-Pacific: Historical Trends, 2018-2023 (USD Billion)
Table 25.136 Bacterial Expression Systems Market in Asia-Pacific: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.137 Yeast Expression Systems Market in Asia-Pacific: Historical Trends, 2018-2023 (USD Billion)
Table 25.138 Yeast Expression Systems Market in Asia-Pacific: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.139 Other Expression Systems Market in Asia-Pacific: Historical Trends, 2018-2023 (USD Billion)
Table 25.140 Other Expression Systems Market in Asia-Pacific: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.141 Recombinant Proteins Market in Asia-Pacific: Historical Trends, 2018-2023 (USD Billion)
Table 25.142 Recombinant Proteins Market in Asia-Pacific: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.143 Enzymes Market in Asia-Pacific: Historical Trends, 2018-2023 (USD Billion)
Table 25.144 Enzymes Market in Asia-Pacific: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.145 Plasmid DNA Market in Asia-Pacific: Historical Trends, 2018-2023 (USD Billion)
Table 25.146 Plasmid DNA Market in Asia-Pacific: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.147 Antibodies Market in Asia-Pacific: Historical Trends, 2018-2023 (USD Billion)
Table 25.148 Antibodies Market in Asia-Pacific: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.149 Other Biologics Market in Asia-Pacific: Historical Trends, 2018-2023 (USD Billion)
Table 25.150 Other Biologics Market in Asia-Pacific: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.151 Small Companies Market in Asia-Pacific: Historical Trends, 2018-2023 (USD Billion)
Table 25.152 Small Companies Market in Asia-Pacific: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.153 Mid-Sized Companies Market in Asia-Pacific: Historical Trends, 2018-2023 (USD Billion)
Table 25.154 Mid-Sized Companies Market in Asia-Pacific: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.155 Large and Very Large Companies Market in Asia-Pacific: Historical Trends, 2018-2023 (USD Billion)
Table 25.156 Large and Very Large Companies Market in Asia-Pacific: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.157 Pharma / Biotech Companies Market in Asia-Pacific: Historical Trends, 2018-2023 (USD Billion)
Table 25.158 Pharma / Biotech Companies Market in Asia-Pacific: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.159 Academic/ Research Institutes Market in Asia-Pacific: Historical Trends, 2018-2023 (USD Billion)
Table 25.160 Academic/ Research Institutes Market in Asia-Pacific: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.161 RoW Market: Historical Trends, 2018-2023 (USD Billion)
Table 25.162 RoW Market: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.163 Bacterial Expression System Market in RoW: Historical Trends, 2018-2023 (USD Billion)
Table 25.164 Bacterial Expression Systems Market in RoW: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.165 Yeast Expression Systems Market in RoW: Historical Trends, 2018-2023 (USD Billion)
Table 25.166 Yeast Expression Systems Market in RoW: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.167 Other Expression Systems Market in RoW: Historical Trends, 2018-2023 (USD Billion)
Table 25.168 Other Expression Systems Market in RoW: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.169 Recombinant Proteins Market in RoW: Historical Trends, 2018-2023 (USD Billion)
Table 25.170 Recombinant Proteins Market in RoW: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.171 Enzymes Market in RoW: Historical Trends, 2018-2023 (USD Billion)
Table 25.172 Enzymes Market in RoW: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.173 Plasmid DNA Market in RoW: Historical Trends, 2018-2023 (USD Billion)
Table 25.174 Plasmid DNA Market in RoW: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.175 Antibodies Market in RoW: Historical Trends, 2018-2023 (USD Billion)
Table 25.176 Antibodies Market in RoW: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.177 Other Biologics Market in RoW: Historical Trends, 2018-2023 (USD Billion)
Table 25.178 Other Biologics Market in RoW: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.179 Small Companies Market in RoW: Historical Trends, 2018-2023 (USD Billion)
Table 25.180 Small Companies Market in RoW: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.181 Mid-Sized Companies Market in RoW: Historical Trends, 2018-2023 (USD Billion)
Table 25.182 Mid-Sized Companies Market in RoW: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.183 Large and Very Large Companies Market in RoW: Historical Trends, 2018-2023 (USD Billion)
Table 25.184 Large and Very Large Companies Market in RoW: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.185 Pharma / Biotech Companies Market in RoW: Historical Trends, 2018-2023 (USD Billion)
Table 25.186 Pharma / Biotech Companies Market in RoW: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.187 Academic/ Research Institutes Market in RoW: Historical Trends, 2018-2023 (USD Billion)
Table 25.188 Academic/ Research Institutes Market in RoW: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenarios (USD Billion)

List Of Companies And Organizations

  1. 3P Biopharmaceuticals
  2. 53Biologics
  3. AbbVie Contract Manufacturing
  4. ABEC
  5. ADL BioPharma
  6. ADM Protexin
  7. AGC Biologics
  8. Ajinomoto Bio-Pharma Services
  9. Aldevron
  10. Almac
  11. Arranta Bio
  12. Aumgene Biosciences
  13. Avantor
  14. Axcellerate Pharma
  15. BacThera
  16. Batavia Biosciences
  17. Bavarian Nordic
  18. BBI Solutions
  19. BiBo Pharma
  20. Binex
  21. Bio Elpida
  22. Biocatalysts
  23. BioCell
  24. BioCina
  25. Biodextris (acquired by Clean Biologics)
  26. BioGeneration Ventures
  27. Bioingenium
  28. Biomar Microbial Technologies
  29. Biomay
  30. BioProduction by Sekisui
  31. Biose
  32. Biosphere
  33. Biosynth
  34. Bio-Synthesis
  35. Biosyntia
  36. Bio-Technology General
  37. BioVectra
  38. Biovian
  39. BioXcellence (CDMO arm of Boehringer Ingelheim)
  40. BJP Laboratories
  41. BOC Sciences
  42. Boston Institute of Biotechnology
  43. Bridgewest
  44. Canton Biologics
  45. Catalent Biologics
  46. Center for Breakthrough Medicines
  47. Cerbios-Pharma
  48. Charles River Laboratories
  49. ChemPartner Biologics
  50. Chr. Hansen
  51. CinnaGen
  52. CJ CheilJedang
  53. Corden Pharma
  54. Creative Biogene
  55. Creative Biolabs
  56. Creative BioMart
  57. Culture Bioscience
  58. Curia
  59. Cytiva
  60. Cytovance Biologics (acquired by Hepalink USA)
  61. EirGenix
  62. EKF Life Sciences
  63. Emergent BioSolutions
  64. Enteris BioPharma
  65. Enzene Biosciences
  66. Etinpro
  67. EuBiologics
  68. EUROAPI
  69. Eurofins
  70. Eurogentec 
  71. Evanoa Bioscience
  72. Evax
  73. EverImmune
  74. Evologic Technologies
  75. Evonik Health Care
  76. Forbion
  77. FUJIFILM Diosynth Biotechnologies
  78. Genome & Company
  79. Genovior 
  80. GenScript ProBio
  81. Gnosis by Lesaffre
  82. GPN Vaccines
  83. GSK
  84. GTP Bioways
  85. Hanmi Pharmaceutical
  86. Helvetic Biopharma
  87. Hong Kong Institute of Biotechnology
  88. HSO Health Care (acquired by Chr. Hansen)
  89. JAFRAL Biosolutions
  90. Jeneil Biotech
  91. Jennewein Biotechnologie
  92. Kanda BioTech
  93. KBI Biopharma
  94. Kemwell Biopharma
  95. Laurus Bio
  96. Leanbio Pro
  97. List Biological Laboratories
  98. Lonza
  99. Menarini Biotech
  100. Meridian Life Science
  101. MicroBiopharm Japan
  102. mk2 Biotechnologies
  103. MyBiotics
  104. Mycenax Biotech
  105. Northway Biotech
  106. Novozymes
  107. NUMAFERM 
  108. Nykode Therapeutics
  109. Olon Biotech
  110. PackGene Biotech
  111. Paras Biopharma
  112. Pfizer
  113. Pfizer CentreOne
  114. Phenotypeca
  115. Polaris Pharmaceuticals 
  116. Polpharma Biologics
  117. Polyplus (Acquired by Sartorius)
  118. Premas Biotech
  119. ProbioFerm
  120. Profacgen
  121. Proventus Bioscience
  122. QUAY Pharma
  123. Quratis
  124. Rebiotix
  125. Recipharm
  126. Reliance Life Sciences
  127. Richter-Helm BioLogics
  128. Sandoz
  129. SBT Instruments
  130. Scientific Protein Laboratories
  131. Scinai Immunotherapeutics
  132. Scorpius Biomanufacturing
  133. Seres Therapeutics
  134. Servier
  135. SGS
  136. Shilpa Biologicals
  137. Siam Bioscience
  138. SK Bioscience
  139. Stelis Biopharma
  140. Syngene
  141. Taron Solutions
  142. Technical University of Munich
  143. Texcell
  144. The Native Antigen
  145. TopAlliance Biosciences
  146. UAS Labs
  147. Unique Biotech
  148. VectorBuilder 
  149. Vectron Biosolutions
  150. VGXI
  151. VxP Biologics 
  152. WACKER
  153. Waisman Biomanufacturing
  154. Worg Pharma
  155. WuXi Biologics
  156. Yapan Bio
  157. Zhejiang Hisun Pharmaceutical 

 

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com